CBX4 and hepatocellular carcinoma: The CBX family, for example, CBX4 has been shown to affect the resistance of hepatocellular carcinoma cells to sorafenib [53], the effect of other members on resistance needs to be further investigated, and these may be research directions to explain the development of drug resistance in DLBCL patients.